Transcriptomic correlates of neurite degeneration due to human brain‐derived Aβ and protection by clinical anti‐Aβ antibodies: Molecular and cell biology/APP/Abeta/amyloid. (7th December 2020)

• Record Type: Journal Article
• Authors: Stern, Andrew; Liu, Wen; Jin, Ming; Walsh, Dominic M.; Selkoe, Dennis J.
• Is Part Of: Alzheimer's & dementia. Volume 16(2020)Supplement 2
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-12-07
• Subjects: Alzheimer's disease -- Periodicals; Alzheimer Disease -- Periodicals; Dementia -- Periodicals; Démence; Maladie d'Alzheimer; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.83
• DOI: 10.1002/alz.043057
• Languages: English
• ISSNs: 1552-5260

Abstract

Abstract: Background: The proximate cause of dementia in Alzheimer disease (AD) is the dystrophy and loss of synapses and neurites, and the eventual death of neurons. Upstream events include hyperphosphorylation and aggregation of tau, and further upstream is the formation of soluble oligomers of Aβ. The molecular details which link these three and other events within the "amyloid cascade" remain murky, but elucidating them will likely reveal new therapeutic targets. Method: To dissect early steps in the Aβ oligomer‐driven neuritotoxicity, we recently developed an in vitro system in which human brain‐derived soluble Aβ is applied to iPSC‐derived human neurons (iNs) to induce neurite degeneration (Jin et al, Nat Commun. 2018; 9(1):2676). Soluble extracts from AD brain were either immunodepleted of Aβ with a polyclonal antiserum or mock‐immunodepleted with rabbit IgG, then applied at 21 DIV to iPSC‐derived neurons that had been induced by Neurogenin‐2 expression. Neurite integrity was tracked using the NeuroTrack module of the IncuCyte ZOOM system for live‐cell analysis. Various humanized anti‐Aβ antibodies were added at concentrations from 0.5 to 3 ug/mL along with the control antibody bevacizumab (Avastin). Result: Immunodepletion with the polyclonal antibody resulted in efficient removal of Aβ. Mock‐immunodepleted, but not immunodepleted, human soluble brain extracts caused quantifiable neuritotoxicity using this unbiased, automated imaging system. These effects were rescued to different degrees by different anti‐Aβ antibodies but not by Avastin. Conclusion: Human AD brain‐derived soluble extracts cause neuritotoxicity to human neurons in an Aβ oligomer‐dependent manner. This effect can be decreased by anti‐Aβ antibodies currently in clinical trials, including aducanumab and BAN2401. We are now performing unbiased transcriptomic and proteomic profiling of the iNs after treatment with human‐derived soluble Aβ oligomers to determine the immediate molecular events that precede and accompany Aβ‐dependent neuritotoxicity. These results will be compared with recently‐published single‐cell transcriptomic data from AD brain to identify potential therapeutic targets.